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ABSTRACT

Substantial evidence has shown that dopamine (DA), particularly in the nucleus accumbens
(NAc), is involved in behavioral activation and effort-related processes, such as overcoming
work related response costs. Behavioral paradigms have been developed to assess effort-related
choice behavior in rodents, including maze procedures and operant tasks. Interference with
accumbens DA transmission through administration of the vesicular monoamine transportor-2
(VMAT-2) inhibitor tetrabenazine (TBZ) produces an alteration of response allocation in the
concurrent FR5/chow choice procedure, biasing animals toward the lower effort alternative. The
effects of TBZ are consistent with DA depletions and administration of DA D1 or D2 family
antagonists. It has been suggested that these drug-induced shifts in effort-related choice behavior
seen in rodents are analogous to symptoms such as psychomotor retardation, anergia, and fatigue,
which can be observed in people with depression and other related disorders. Previous studies
have shown the effects of TBZ on lever pressing and chow consumption can be attenuated
through co-administration of the putative antidepressant MSX-3, an adenosine A2A antagonist,
the monoamine-oxidase (MAO)-B inhibitor, deprenyl, as well as the well-known antidepressant
bupropion. Recently, clinical studies have shown antidepressant efficacy of curcumin, a MAOA/B inhibitor, as an adjunct medication. Curcumin is a naturally occurring compound found in
turmeric, a prominent ingredient of curry powder used in ethnic foods. Curcumin has proven
successful in traditional rodent models of depression such as the tail suspension or forced swim
test. The current study investigated the ability of curcumin to reverse the effects of TBZ on
effort-related choice behavior. The effects of TBZ on lever pressing were partially reversed by
ingestion of a high dose of curcumin two hours prior to testing. A major problem with curcumin
is its poor bioavailability due to fast metabolism; therefore future studies should investigate ways
to enhance the absorption of curcumin.

1 - Introduction
To survive, organisms must overcome environmental obstacles that separate them from
motivationally significant stimuli. In order to overcome constraints, organisms need to exert
effort through effort-related decision-making revolving around cost/benefit analyses (Salamone
& Correa, 2002). There are numerous variables that influence these choices, with one of the most
important being interactions based upon work requirements and reinforcement value (Salamone
& Correa, 2002; Salamone et al., 2003, 2005, 2007). Substantial evidence has indicated that the
mesolimbic dopamine (DA) pathway, particularly DA within the nucleus accumbens (NAc), is
involved in effort-related processes, such as overcoming work-related response costs in
instrumental behavior (Barbano & Cador, 2007; Phillips et al., 2007; Salamone et al., 2005,
2007). Interference with DA transmission can affect the relative allocation of behavior in animals
responding on tasks that assess effort-based choice behavior; biasing animals towards the lower
effort alternative (Floresco et al., 2008; Salamone et al., 2005, 2007).
Tests of effort-related choice behavior offer animals choices between a more highly
valued reward that can be obtained by a high degree of effort vs. a low effort/low reward option.
One procedure that is used to study the effects of dopaminergic manipulations on effort-related
choice behavior is the concurrent FR5/chow feeding choice task. This operant choice task offers
rats the option of lever pressing to obtain a more preferred food (BioServe high carbohydrate
pellets), or approaching and consuming a concurrently available less preferred standard lab chow.
Under baseline or control conditions, when the FR requirement is relatively low (i.e., FR1 or
FR5), trained rats will receive most of their food from lever pressing and consume only a small
quantity of the lab chow (Cousins et al., 1993; Nowend et al., 2001; Salamone et al., 1991, 1997).
Interfering with DA neurotransmission through DA depletions and local or systemic
administration of DA D1 or D2 family antagonists produce a reallocation of behavior, such that

lever-pressing is significantly decreased and consumption of the lab chow is increased (Nunes et
al., 2010; Salamone et al., 2002; Sink et al., 2008; Worden et al., 2009). A similar behavioral
profile is produced after administration of the reversible vesicular monoamine transporter-2
(VMAT-2) inhibitor tetrabenazine (TBZ). By inhibiting VMAT-2, TBZ blocks vesicular storage
and depletes monoamines, with its greatest impact being upon striatal DA (Pettibone et al., 1984).
Additionally, TBZ has been shown to affect DA signal transduction in a manner that is consistent
with reduced ventral striatal DA D1 and D2 receptor neurotransmission (Nunes et al., 2013). The
concurrent FR5/chow choice task has been extensively validated to demonstrate that the effects
of interference of NAc DA transmission are not due to changes in appetite, food intake, or
preference (Salamone et al., 1991), and do resemble effects of reinforced evaluation by
prefeeding (Nunes et al., 2013; Salamone et al., 1991) or appetite suppressant drugs (Salamone et
al., 2002; Sink et al., 2008).
It has been suggested that tasks measuring effort-based decision-making could be useful
to model the effort-related motivational symptoms such as fatigue, psychomotor slowing, and
anergia seen in depression and other related disorders (Salamone & Correa, 2012). It has been
reported that these symptoms are among the most common in psychiatric medicine but are the
most difficult to treat as they are resistant to antidepressant treatment (Fava et al., 2013; Stahl,
2002). Therefore, these paradigms may be beneficial for developing adjunct medication to treat
these motivational dysfunctions. Tests of effort-related decision-making have been developed in
humans (Treadway et al., 2011), and have shown that individuals with major depressive disorder
show reduced selection of higher effort alternatives (Treadway et al., 2012). Reversal studies
(e.g., co-administration of another compound) are used as pre-clinical assessment of potential
treatments. Co-administration of the adenosine A2A antagonist, MSX-3, was able to attenuate the
shifts in behavior induced by TBZ (Nunes et al., 2013). Additionally, the widely used

antidepressant drug bupropion, a catecholamine uptake blocker, and L-deprenyl, a monoamine
oxidase-B (MAO-B) inhibitor, attenuate the effort-related shifts induced by TBZ (Nunes et al.,
2013; Randall et al., submitted).
Curcumin is a naturally occurring compound found in turmeric powder, that has been
shown to possess action as an inhibitor of both MAO-A and MAO-B enzymes (Kulkarni et al.,
2005). By inhibiting the activity of monoamine oxidase, curcumin prevents the breakdown of
monoamines and thereby increases their availability. Levels of both serotonin (5-HT) and DA
were increased following administration of curcumin, and levels of norepinephrine (NE) were
not altered (Kulkarni et al., 2008). There is a dose-dependent effect of curcumin on the MAO-B
enzyme. Curcumin’s action on this enzyme is achieved at high doses as compared to inhibition
of the MAO-A enzyme which is achieved a low doses (i.e., 5 mg/kg vs. 40 mg/kg; Kulkarni et al.,
2008). The antidepressant profile of curcumin has been explored in animal models of behavioral
despair, which are employed as antidepressant screening paradigms. Co-administration of
curcumin with DA depleting agents, such as reserpine, decreased immobility time (Kulkarni et
al., 2008). Moreover, curcumin further enhanced the anti-immobility effect of the nonselective
MAO inhibitor, tranylcypromine, as well as selegiline, a MAO-B inhibitor, in the mouse forced
swim test (Kulkarni et al., 2008). Together these studies confirm the MAO inhibiting activity of
curcumin. Recently, curcumin has been shown to be effective in human-clinical trials as an
adjunct medication for depression (Bergman et al., 2013).
Previous studies that have investigated the antidepressant-like effects have administered
curcumin orally via gavage feeding (Kulkarni et al., 2008; Xu et al., 2005). Gavage is the
introduction of a solution into the stomach by means of inserting a small-diameter tube into the
esophagus, and delivering the drug directly into the stomach by means of a syringe. Although
highly effective, this method can cause esophageal injury as well as restraint-associated distress,

particularly with repeated use (Brown et al., 2000). Stress induced alterations include changes in
gastric secretion and mobility, changes in heart rate and increases in plasma glucocorticoids
(Kent et al., 1986; Brown et al., 2000). Moreover, this stress-induced response can last up to one
hour after (Bonnichsen et al., 2005). A prior study reported a 32% mortality rate attributed to
granulomatous inflammation caused by gavaging that ultimately lead to asphyxia (Germann &
Ockert, 1994).
The aim of the current study is to investigate the effects of ingested curcumin pellets to
attenuate TBZ induced shifts in behavior in rodents responding on the concurrent FR5/chow
choice procedure. Self-administration of curcumin pellets by animals will reduce adverse effects
and distress due to gavaging and thereby provides an alternative to gavage. In addition, blood
assays and tissue harvesting were conducted to determine rate of absorption and metabolism of
curcumin.

2. Materials and Methods
2. 1 Animals
Adult male Sprague-Dawley rats (Harlan-Sprague Dawley, Indianapolis, IN, USA) were
pair housed in a colony maintained at 23° C with 12-h light/dark cycles (lights on at 7:00h). Rats
(n=7) weighed approximately 300-350 grams at the beginning of the study, and were initially
food restricted to 85% of their free-feeding body weight for operant training. Rats were fed
supplemental chow to maintain the food restriction throughout the study, with ad libitum water,
and were allowed modest weight gain throughout experiments. Animal protocols were approved
by the University of Connecticut institutional animal care and use committee, and followed NIH
guidelines.
2.2 - Pharmacological Agents and Dose Selection

Tetrabenazine (9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7, 11b
hexahydrobenzo[a]quinolizin-2-one), the VMAT-2 inhibitor, was purchased from Tocris
Bioscience (Bristol, UK). Tetrabenazine was dissolved in a vehicle solution of 0.9% saline
(80%) and DMSO (20%). 1N HCl /mL volume was then added to adjust the pH and get the drug
completely into solution. The final pH of the tetrabenazine solution was 3.5. The saline with 20%
DMSO vehicle solution was administered as the vehicle control. The 0.75 mg/kg dose of
tetrabenazine which was used for the FR5/chow choice task was based on extensive pilot work
done in our laboratory. All injections were administered intraperitoneal (IP).
Curcumin pellets were formulated by grinding 28 mg of BioServe (Frenchtown, NJ,
USA) and 7 mg of curcumin together, to give a total weight of 35 mg per pellet. Curcumin
pellets were pressed fresh weekly and were stored in a desiccator. All pellets were made by the
University of Connecticut, School of Pharmacy. The dosages of curcumin were adjusted by
pellet number. Animals needed to consume at least half of the pellets to be considered successful
in achieving the desired dose.
2.3 Behavioral Procedures
Concurrent FR5/chow-choice procedure: Behavioral sessions were conducted in operant
conditioning chambers (28x23x23 cm3, Med Associates, Georgia, VT, USA) during the light
period. Rats (n = 9) were initially trained to lever press on a continuous reinforcement schedule
(30 minute sessions, during 5 days/week) to obtain 45mg pellets, (Bioserve, Frenchtown, NJ,
USA), and then were shifted to the FR5 schedule (30 minute sessions, 5 days/week) and trained
for several additional weeks until reaching a predetermined baseline number of lever presses (i.e.,
consistent responding • 1,200 lever presses). Animals needed to consistently reach baseline
criteria for the course of approximately one week before being introduced to the concurrent
FR5/chow-feeding choice procedure. In this task, weighed amounts of laboratory chow

(Laboratory Diet, 5P00 Prolab RHM 3000, Purina Mills, St. Louis, MO, USA; typically 20-25
grams, four-five large pieces) were concurrently available in the chamber during the 30 min FR5
session. Rats also received feeding study training and were trained to consume 10 Bioserve
pellets on baseline days 2 hours prior to running. Before inclusion in the experiment, all animals
were exposed to 10 (highest dose, 160 mg/kg) curcumin to insure consumption. Animals were
trained on the procedure until approximately the entire dosage (i.e., 8/10 pellets) was consumed.
On experimental testing days, when TBZ was administered, the rats were administered 80 mg/kg
and 160 mg/kg of the curcumin pellet formulation 2 hours prior to running. At the end of the
FR5/chow choice session, rats were immediately removed from the chambers, lever pressing
totals were recorded, and amount of chow consumed was determined by weighing the remaining
food and spillage. Rats were trained until reaching and maintaining stable levels of baseline lever
pressing and chow intake. Once animals achieved baseline rates experimental testing began.
2.4 Experimental Procedures
Animals received a vehicle injection one week prior to beginning testing in order to
habituate them to being injected. Additionally, animals received curcumin pellets one week
prior to testing in order to assure accurate consumption. All experiments used a within-group
design in which each rat received all drug or vehicle treatments in the experiment in a randomly
varied order (one treatment per week). Baseline training sessions (i.e., non-drug) were conducted
4 days per week.
2.4.1 Experiment 1: Ability of MAO-inhibitor curcumin to reverse the effects of TBZ.
Rats were trained before drug testing as described above. Rats (n=7) were given 15 minutes to
consume pellets administered 2 hours prior to testing. Animals received the following
treatments; vehicle plus 10 Bioserve pellets (VEH/BIO), tetrabenazine plus 10 Bioserve pellets
(TBZ/BIO), tetrabenazine plus 80 mg/kg curcumin (TBZ/80), and tetrabenazine plus 160 mg/kg

curcumin (TBZ/160). Animals who were over 400 grams, received one extra pellet. Remnants of
the pellets were collected and weighed to determine the total dose of curcumin administered.
Next, rats received an injection of either 0.75 mg/kg TBZ or vehicle 90 minutes prior to testing.
2.4.2 Experiment 2: Assays of tissue levels of curcumin to determine rate of absorption
Rats were randomly assigned to consume either 80 or 160 mg/kg curcumin 2 hours prior to live
decapitations. Animals were placed into CO2 for approximately 2 minutes and were quickly
removed. Cardiac punctures were performed to acquire at least 5 cc’s of blood. Afterwards, the
liver, brain, and small intestine were removed for analysis.
2.5 Data Analysis
In experiment 1, total number of lever presses and gram quantity of chow intake from the 30 min
session were analyzed using repeated measures ANOVA. A computerized statistical program
(SPSS 21.0 for Windows) was used to perform all analyses. When there was a significant
ANOVA, non-orthogonal planned comparisons using the overall error term were used to assess
the differences between each treatment and the control condition. The number of comparisons
was restricted to the number of treatments minus one (Keppel, 1991). For the effect size
calculations partial eta-squared was used (η ρ ²). In experiment 2, a bivariate correlation was run
between dose of curcumin administered and curcumin tissue concentration. Pearson’s correlation
coefficient (r) was used to determine the linear dependence between the two variables.
3. Results
Experiment 1: Ability of curcumin to reverse the effects of TBZ.
The MAO A/B inhibitor, curcumin, produced a partial reversal of the effects of TBZ in
animals tested on the FR5/chow feeding choice test (Figure 1). Repeated measures ANOVA
showed that there was an overall significant effect of drug treatment on lever pressing
[F(3,18)=10.17, p<0.001]. Planned comparisons revealed that TBZ produced a significant

reduction in lever pressing compared to vehicle control conditions (p<0.05). Co-administration
of 160 mg/kg curcumin with TBZ significantly increased lever pressing compared to TBZ plus
vehicle (planned comparisons, p<0.05). The drug treatment effect was marked by a moderately
high effect size (η

2

= 0.629). The overall treatment effect for chow consumption was also

statistically significant [F(3,18)=12.121, p<0.001]. Chow intake was significantly increased by
TBZ relative to the vehicle-vehicle condition (planned comparisons, p<0.05). Chow intake was
significantly reduced at the 160 mg/kg dose of curcumin (planned comparisons, p<0.05). The
effect size of drug treatment on chow consumption was moderately high (η 2 = 0.669). Thus, coadministration of curcumin (160 mg/kg) with TBZ significantly increase lever pressing and
decreased chow consumption compared to TBZ-vehicle treated animals.
Experiment 2: Assays of tissue levels of curcumin to determine rate of absorption
The bioavailability of curcumin despite the dose administered produced similar blood
serum concentrations (Figure 2). A bivariate correlation between dose consumed and
concentration revealed that 80 and 160 mg/kg produced nearly identical levels. There was a very
strong correlation for both 80 mg/kg (r=0.918) and 160 mg/kg (r=0.907).
4. Discussion
TBZ is currently used to treat Huntington’s disease, and is known to produce depressive
side effects, including motivational symptoms, in some patients (Frank et al., 2009; 2010). By
inhibiting VMAT-2, TBZ affects monoamine storage, but studies indicate that the greatest
effects are on striatal DA (Pettibone et al., 1984; Nunes et al., 2013). Similar to the effects
produced by interfering with NAc DA, TBZ produced a shift in choice behavior in rats
responding on the concurrent FR5/chow choice task. Compared to control animals, TBZ-treated
animals have decreased lever pressing and increased consumption of the lab chow. Animals
administered TBZ expend minimal effort when an alterative food source is available at lower

cost (i.e., the freely available chow). Although TBZ-treated rats show significant reductions in
food-reinforced lever pressing, they remained directed towards the acquisition and consumption
of food. Similar to the effects produced by administration of DA D1 or D2 family antagonists, the
effects induced by TBZ substantially differed from pre-feeding to reduce food motivation
(Salamone et al., 1991), and appetite suppressant drugs such as amphetamine (Cousins et al.,
1994) and CB1 antagonists and inverse agonists (Sink et al., 2008), all of which failed to increase
chow consumption at doses that suppressed lever pressing.
The TBZ induced shifts in behavior can be attenuated by co-administration of the
adenosine A2A antagonist, MSX-3, the catecholamine uptake inhibitor bupropion, and the MAOB inhibitor deprenyl (Nunes et al., 2013; Randall et al., submitted). The present study
investigated the MAO-A and B inhibitor, curcumin, to reverse the behavioral effects of TBZ.
Co-administration of 160mg/kg curcumin two hours prior testing can successfully attenuate TBZ
induced effects. Previously, curcumin has been shown to produce antidepressant-like effects in
rodent tasks such as the forced swim test (Xu et al., 2005) and the tail suspension task (Xu et al.,
2005). Curcumin produces effects in these paradigms that are comparable to well-known
antidepressants such as fluoxetine, desipramine, and imipramine (Lucki, 1997). The ability of
curcumin to attenuate the shift in behavior is similar to the MAO-B inhibitor l-deprenyl (Randall
et al., submitted). Moreover, in antidepressant screening paradigms curcumin has been combined
with subthreshold doses of antidepressants, and has further attenuated immobility time
(Sanmukhani et al., 2011). In addition, a recent human clinical trial has paired curcumin as an
adjunct medication to treatment with fluoxetine (Prozac) for depression (Sanmukhani et al.,
2013). Patients with add-on curcumin plus fluoxetine had a better ranking on the Hamilton
Depression Rating Scale compared to those without curcumin (Sanmukhani et al., 2013). Taken
together, these studies suggest that curcumin could further potentiate current antidepressants.

Previous studies have administered the dopamine norepinephrine reuptake inhibitor, bupropion,
with TBZ in operant task (Nunes et al., 2013; Randall et al., submitted) and maze paradigms
(Yohn et al., submitted). Bupropion, like l-deprenyl and curcumin, also produced a partial
reversal of TBZ induced deficits in choice behavior (Nunes et al., 2013; Randall et al.,
submitted; Yohn et al., submitted). Future studies should investigate the ability of subthreshold
doses of bupropion plus curcumin to attenuate effort-related shifts in behavior caused by TBZ.
Various animal models (Shankar et al., 1980) or human clinical studies (Lao et al., 2006)
have proved that curcumin is extremely safe even at high doses. The pharmacological safety of
curcumin makes it a potential compound for the treatment of depression, however, a major issue
with curcumin is that is has very poor bioavailability. Curcumin has low intrinsic activity, high
rate metabolism and poor absorption (Anand et al., 2007). Previous studies have indicated that
the route of administration plays a role in achievable serum levels and tissue distribution (Anand
et al., 2007). For instance a study conducted by Ravindranath & Chandrasekhara (1981) revealed
less than 3% of curcumin was found in the liver, small intestine, and stomach tissues at the
highest dose of curcumin. Moreover, the percentage of curcumin absorbed remained constant
regardless of dose, indicating that administration of more curcumin does not result in higher
absorption (Ravindranath & Chandrasekhara, 1981). Similarly, the blood serum results from the
current study are consistent with the literature. The concentration of curcumin in blood serum is
independent of dosage. For example, both the 80 and 160 mg/kg dose of curcumin displayed
roughly the same total concentration of curcumin. Additionally, previous studies have shown that
curcumin has extremely low serum levels (Anand et al., 2007). Similar to rodents, oral
administration of 2 grams curcumin daily in humans produced undetectable serum levels (Cheng
et al., 2001). Together, these studies with the current results suggest there is a dose-dependent
limitation to bioavailability. The addition of an excipient to curcumin has been shown to improve

the bioavailability (Anand et al., 2007; Kulkarni et al., 2008; Shoba et al., 1998). Therefore,
future studies should investigate the potential of curcumin paired with an adjuvant.
Neusilin has been proposed as a possible bioavailability enhancer that may be paired with
curcumin (Williams et al., 2014; Yan et al., 2011). Using curcumin prepared with phytosomes
has also been shown to improve the uptake into the blood (Marczylo et al., 2007), and that the
peak of curcumin in blood is 15 minutes after oral gavage administration. Other studies have
used piperine, another natural compound found primarily in hot jalapeno peppers, to increase the
bioavailability of oral curcumin dosing by 154% (Kulkarni et al., 2008; Shoba et al., 1998).
Piperine’s combined effects with curcumin have also been studied examining the anti-depressant
like effect on chronic-stress induced behavior (Bhutani et al., 2009). Prior studies have
demonstrated that piperine enhances the oral bioavailability of curcumin in both rats and humans
at doses that were devoid of adverse side effects (Shoba et al., 1997). Piperine has been shown to
inhibit the metabolism of curcumin and enhance its bioavailability.
Additionally, during collection it was noted that, majority of the curcumin pellets were
still located within the stomach and small intestine. Taking this into consideration, future studies
should extend the lead-time of curcumin. Prior studies have found that curcumin remains active
in the system 90 minutes to three hours after administration (Anand et al., 2007). Moreover,
previous studies have used IP or oral injections of curcumin, which have faster absorption rates
(Pan et al., 1999). Prior studies have shown that negligible amounts of curcumin have been found
in blood plasma of rats after oral administration of 1 g/kg of curcumin indicating that curcumin
was poorly absorbed from the gut (Wahlstrom & Blennow, 1978). Since very little curcumin is
absorbed from the gut and small intestine, future studies should investigate rate of absorption of
curcumin with an excipient.

As mentioned before, curcumin has already been employed in studies testing its effects
as an enhancer of antidepressant medication (Kulkarni et al., 2008; Sanmukhani et al., 2013).
With the results from this study, we provide further evidence that it can be used for depression,
schizophrenia, and other related disorders that have motivational symptoms.

People with

neurological disorders, especially those related to inflammation, may consider using curcumin as
a natural herbal remedy, by suggesting a change of diet involving an increased intake of curry
foods. This adds to the growing field of complementary and alternative medicine, and may be
able to help those who cannot take the normally prescribed medications due to either medical or
personal reasons.
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Figure 1: The effects of the MAO-A/B inhibitor curcumin on TBZ-induced changes in rats
performing on the concurrent FR5/chow choice task. Rats received IP injections of vehicle or
0.75 mg/kg 90 minutes prior to testing. In addition, rats were administered curcumin two hours
prior to testing. (A) Mean (±SEM) number of lever presses (FR5 schedule) during the 30 minute
session. (B) Mean (±SEM) gram quantity of chow intake. TBZ significantly decreased lever
pressing and increased chow consumption relative to vehicle (# p<0.05). Administration of 160
curcumin to TBZ-treated rats 2 hours prior to testing significantly increased lever pressing and
decreased chow consumption relative to treatment with TBZ alone (* p<0.05).

44

Curcumin Consumed (mg)

42

A

40

38

36

34

32

30
0

200

400

600

800

1000

1200

500

600

Curcumin Measured (ng/g)

78

Curcumin Consumed (mg)

B
76

74

72

70

68
0

100

200

300

400

Curcumin Measured (ng/g)

Figure 2: Blood serum concentrations of curcumin to assess rate of absorption. Rats received
either 80 or 160 mg/kg curcumin two hours prior to collection. (A) Linear trend with a strong
positive correlation of the amount of curcumin consumed and serum levels in the 80 mg/kg dose
(r=0.918). (B) Positive correlation of the effects of 160 mg/kg curcumin on amount detectable in
blood serum (r=0.907). Despite the dose and amount consumed, both doses have similar serum
concentration levels.

